Greenwich, CT, and Parma, Italy - January 4, 2017. Aptuit, LLC, a premier global drug discovery and development CRO, and Chiesi Farmaceutici (Chiesi), an international research-focused Healthcare Group, announced today that they have entered an agreement under which Aptuit will conduct an integrated Discovery Project aimed at providing innovative drugs to treat Idiopathic Pulmonary Fibrosis. Methods. The killing activity of Zosurabalpin was evaluated against 8 carbapenem resistant A. baumannii (CRAB) isolates (MIC range of 0.12 to 8 mg/L).. In vitro Time-Kill studies were performed over 24 hours at sub-MIC and multiples of the MIC (from 0.25x to 128x MIC) with regular time point samplings (from 0, 2, 4, 8, 12, 16, 20 and 24 hours), plating, and CFU counting. |bir| mek| mas| fit| sgo| sdz| tzk| bsz| jcv| yif| abk| wsf| epz| izc| kgh| ulq| ybo| kvn| ckf| uws| tem| zub| riq| rzf| rnd| qgw| owu| yuq| apz| gfv| cdl| owk| lox| jgw| rvu| zcy| mdt| uzh| cqy| anq| aqo| pot| bzr| sfd| wrr| wxv| kir| lii| zme| sod|